» Articles » PMID: 31323244

Cell-penetrating Peptide: a Means of Breaking Through the Physiological Barriers of Different Tissues and Organs

Overview
Specialty Pharmacology
Date 2019 Jul 20
PMID 31323244
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

The selective infiltration of cell membranes and tissue barriers often blocks the entry of most active molecules. This natural defense mechanism prevents the invasion of exogenous substances and limits the therapeutic value of most available molecules. Therefore, it is particularly important to find appropriate ways of membrane translocation and therapeutic agent delivery to its target site. Cell penetrating peptides (CPPs) are a group of short peptides harnessed in this condition, possessing a significant capacity for membrane transduction and could be exploited to transfer various biologically active cargoes into the cells. Since their discovery, CPPs have been employed for delivery of a wide variety of therapeutic molecules to treat various disorders including cranial nerve involvement, ocular inflammation, myocardial ischemia, dermatosis and cancer. The promising results of CPPs-derived therapeutics in various tumor models demonstrated a potential and worthwhile scope of CPPs in chemotherapy. This review describes the detailed description of CPPs and CPPs-assisted molecular delivery against various tissues and organs disorders. An emphasis is focused on summarizing the novel insights and achievements of CPPs in surmounting the natural membrane barriers during the last 5 years.

Citing Articles

Biomineralize Mitochondria in Metal-Organic Frameworks to Promote Mitochondria Transplantation From Non-Tumorigenic Cells Into Cancer Cells.

Zhou J, Liu C, Wang Y, Guo Y, Xu X, Vuorimaa-Laukkanen E Smart Med. 2025; 4(1):e134.

PMID: 40059964 PMC: 11862567. DOI: 10.1002/smmd.134.


Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.


An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule (FhHDM-1.C2) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis.

Lalor R, Tanaka A, Shiels J, Dixit A, Hoadley S, Dufourd E FASEB J. 2025; 39(4):e70380.

PMID: 39950309 PMC: 11826375. DOI: 10.1096/fj.202400793RR.


Emerging Nanoparticle-Based Diagnostics and Therapeutics for Cancer: Innovations and Challenges.

Puttasiddaiah R, Basavegowda N, Lakshmanagowda N, Raghavendra V, Sagar N, Sridhar K Pharmaceutics. 2025; 17(1).

PMID: 39861718 PMC: 11768644. DOI: 10.3390/pharmaceutics17010070.


Peptide-Oligonucleotide Conjugation: Chemistry and Therapeutic Applications.

Malinowska A, Huynh H, Bose S Curr Issues Mol Biol. 2024; 46(10):11031-11047.

PMID: 39451535 PMC: 11506717. DOI: 10.3390/cimb46100655.